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Susanne Marschner, 3 Raymond P. Goodrich, 3 and Philip J. Norris 1, 2 BACKGROUND: Allogeneic blood transfusion can result in an immune response against major histocompatibility complex (MHC) antigens, potentially complicating future transfusions or transplants. We previously demonstrated that pathogen reduction of platelet-rich plasma (PRP) with riboflavin and ultraviolet light (UV1R) can prevent alloimmunization in mice. A similar pathogen-reduction treatment is currently under development for the treatment of whole blood using riboflavin and a higher dose of UV light. We sought to determine the effectiveness of this treatment in the prevention of alloimmunization.
STUDY DESIGN AND METHODS: BALB/cJ mice
were transfused with untreated or UV1R-treated, allogeneic C57Bl/6J whole blood with or without leukoreduction. Mice were evaluated for donor-specific antibodies, ex vivo splenocyte cytokine responses, and changes in the frequency of regulatory T (T reg ) cells.
RESULTS: UV1R treatment blocked cytokine priming
and reduced anti-MHC alloantibody responses to transfused whole blood. Leukoreduction reduced alloantibody levels in both the untreated and UV1R-treated groups. Mice transfused with UV1R-treated whole blood had reduced alloantibody and cytokine responses when subsequently transfused with untreated blood from the same donor type. This reduction in responses was not associated with increased T reg cells.
CONCLUSIONS:
Pathogen reduction of whole blood with UV1R significantly reduces, but does not eliminate, the alloimmune response. Exposure to UV1R-treated whole blood transfusion does appear to induce tolerance to alloantigens, resulting in reduced anti-MHC alloantibody and cytokine responses to subsequent exposures to the same alloantigens. This tolerance does not appear to be driven by an increase in T reg cells.
A llogeneic blood transfusion can expose recipients to a range of foreign antigens capable of stimulating an immune response, and alloimmunization toward donor major histocompatibility complex (MHC) antigens found on donor white blood cells (WBCs) and platelets is common after transfusion. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] These immune responses against foreign MHC can be problematic for patients, resulting in complications such as platelet refractoriness and transplant rejection. 6, [11] [12] [13] [14] [15] Efforts to remove the WBCs from transfused products has significantly reduced the rates of alloimmunization; however, even with leukoreduction, alloimmunization remains a problem. 5, [8] [9] [10] [16] [17] [18] [19] Pathogen reduction, in which blood products are irradiated with ultraviolet light (UV) in the presence of a ABBREVIATIONS: ECP 5 extracorporeal photopheresis; MHC 5 major histocompatibility complex; PRP 5 plateletrich plasma; PRT 5 pathogen reduction technology. photosensitizer (either riboflavin or a psoralen), was designed to reduce the risk of transfusion transmission of infectious disease by inactivating pathogens. Donor WBCs are also effectively killed by this treatment, helping to reduce the risk of graft-versus-host disease. 20, 21 Surprisingly, UV treatment also appears to render these donor WBCs nonimmunogenic in vitro. 22 This is likely the result of down-regulation of surface adhesion molecules, which prevents cell conjugation between treated donor cells and host T cells, blocking direct recognition of donor alloantigens. 23 In mice, the treatment of allogeneic platelet-rich plasma (PRP) with UV plus riboflavin (UV1R) virtually eliminates alloimmunization to primary exposure and significantly reduces alloantibody responses to repeated exposure. 24, 25 Leukoreduction also significantly reduces the levels of antibody in these mice, with the best protection from repeated exposure observed by combining leukoreduction and UV1R treatment. 24, 25 Furthermore, when splenocytes collected from mice transfused with UV1R-treated PRP are exposed to untreated donor cells ex vivo, they have a na€ ıve cytokine production profile, suggesting a lack of priming in vivo. When mice that receive UV1R-treated PRP are subsequently transfused with untreated PRP from the same donor type, these na€ ıve ex vivo cytokine profiles are maintained, suggesting some form of induced tolerance to these alloantigens. This "tolerance" does not extend to antibody generation, because these mice generate antibodies at the same levels as mice that receive only a single untreated PRP transfusion. 24 The effects of UV-based pathogen reduction on MHC alloimmunization in the clinical setting have been difficult to assess, because currently approved products are only available for platelets and plasma, and most recipients are also exposed to untreated allogeneic red blood cell (RBC) units, making it difficult to evaluate changes in alloimmunization that might occur with treatment. Despite these other alloexposures, it has been demonstrated that UV treatment of allogeneic platelets offers some protection from MHC alloimmunization. 1, 12, 26 In addition, transfusion with UV-treated cells has demonstrated immunomodulatory effects in other settings, such as extracorporeal photopheresis (ECP). For ECP, autologous WBCs are collected by apheresis, treated with a psoralen and UV, and returned to the patient; these returned WBCs can then down-modulate damaging immune responses like those seen in autoimmune disease and graft rejection. [27] [28] [29] [30] This immunomodulatory effect appears to result from the induction of a tolerogenic dendritic cell phenotype and regulatory T (T reg ) cells. 31, 32 All of these UV-based treatments use different doses and wavelengths of UV light, which, in addition to the use of different photosensitizers, may impact alloimmunization outcomes. Currently, there are no approved methods for pathogen reduction of RBCs or whole blood in the United States, but two approaches are under development. One uses a chemical compound to cross-link nucleic acids in the absence of UV, and the other uses the same UV1R combination that has been used for the treatment of platelets and plasma but with an increased dose of UV to compensate for UV light absorption by hemoglobin. This UV1R approach was CE-marked (approved for sale in the Europe) at the end of 2015. The hope with these new approaches is that they will close the protective gap left by the transfusion of untreated RBC units alongside treated platelet and plasma components. Both treatments have been shown to be effective at killing pathogens in vitro [33] [34] [35] [36] [37] [38] [39] [40] [41] ; and more recently, UV1R pathogen reduction has been shown to effectively prevent the transmission of malaria in whole blood transfusion. 36, 42 The need for pathogen reduction technology (PRT) for whole blood recently was underlined by the Zika virus outbreak in Puerto Rico, which temporarily halted blood collection on the island. 43 The treatment of whole blood would provide an additional opportunity to treat before separation into components and would provide protection where whole blood is currently transfused. Although blood component therapy predominates in the developed world, whole blood transfusion is currently used in some military settings [44] [45] [46] and in many developing countries, [47] [48] [49] [50] and some have argued that whole blood is preferable for a subset of patients. 45, 51, 52 In the case of the military, fresh whole blood is used when transportation and storage of components are not feasible or are insufficient to keep up with demand-the same settings in which comprehensive blood screening is not available. 44, 52 Although all military personnel are screened for or immunized against many blood-borne pathogens, and some rapid tests are available, there is still an elevated risk of transmission in this population. 53, 54 Many developing countries that lack the infrastructure and resources for blood-component therapy, leukoreduction, and screening also have higher risks of infection in the donor population. A single treatment for whole blood that could neutralize a wide range of pathogens as well as leukocytes may provide a more feasible approach to protecting whole blood transfusion recipients. Little is known about the impact of whole blood pathogen reduction on alloimmunization. A recent study using UV1R pathogen reduction found that it did not prevent alloimmunization against RBC antigens in mice. 55 Responses to MHC alloantigens may be different for several reasons, including the possibility of direct recognition by T cells and expression on WBCs and platelets rather than RBCs, which are impacted differently by treatment. It has been demonstrated that WBCs are inactivated by this treatment. 33, 56 In this study, we used a murine model to determine the impact of UV1R pathogen reduction in whole blood on MHC alloimmunization. Specifically, we evaluated alloantibody generation and WBC priming in recipients of treated versus untreated allogeneic whole blood transfusions. In addition, we assessed how these exposures impact responses to subsequent allogeneic transfusions.
MATERIALS AND METHODS

Mice
Female BALB/cJ mice between 9 and 11 weeks old were used as recipients, and female C57Bl/6J mice between 2 and 6 months old were used as donors. All mice were purchased from the Jackson Laboratory (Bar Harbor, ME) and were maintained in a specific pathogen-free vivarium under barrier conditions at Blood Systems Research Institute (San Francisco, CA). All research was performed with approval and oversight of the Institutional Animal Care and Use Committee at PMI Preclinical, LLC under Animal Welfare Assurance A3367-01.
Donor blood collection
Whole blood was collected by orbital enucleation from multiple donor mice into a single tube containing citratephosphate-dextrose (CPD) anticoagulant (Sigma) at 14% final volume and gently mixed between collections. For experiments involving leukoreduction, filtration was done using neonatal leukoreduction filters (Purecell NEO, Pall) under sterile conditions before any UV1R treatment. Blood was untreated or was treated with UV1R and then stored at room temperature until it was used (within 4 hr of collection).
UV1R treatment
Riboflavin was added to whole blood for a final concentration of 6.6% and then plated in 12-well plates with 0.5mL/ well. Plate lids were replaced with a sheet of bag material cut from a riboflavin and UV light PRT Illumination/Storage bag and a quartz cover to mimic conditions of treatment for typical large volumes. The plate was then treated with a scaled dose of UV light, of 100 J/mL RBCs , determined by volume and hematocrit. Blood was then transferred to sterile tubes for transfusion.
Sample collection and processing
Recipient mice were killed 2 weeks after their final transfusion by exsanguination by orbital enucleation under inhalation anesthesia (isoflurane), followed by spleen collection. Serum was separated from collected blood by centrifugation, then aliquoted, and frozen for future use. Spleens were minced between sterile frosted-glass slides, strained through a 100-mm cell strainer (BD Falcon), and centrifuged over a Ficoll layer to separate light density cells. These cells were washed and counted and were either used fresh or transferred to a freezing media containing 7.5% dimethyl sulfoxide in fetal bovine serum and frozen in liquid nitrogen for future use.
Alloantibody detection
Antibodies were measured as previously described. 25 Briefly, C57Bl/6J splenocytes (donor-type target cells) were preincubated with an anti-FcR blocking antibody, then incubated with the serum to be screened, and washed. Cells were then stained with a biotin-conjugated anti-immunoglobulin j (anti-Igj) antibody to detect bound antibody along with antibodies against B220 as a B-cell marker and T-cell receptor b (TCRb) as a T-cell marker. Cells were then washed and stained with streptavidin allophycocyanin, washed, fixed, and run on a flow cytometer (LSRII; BD Biosciences, San Jose, CA); and 10,000 T-cell events (TCRb-positive, B220-negative) were acquired. The median fluorescent intensity (MFI) of Igj staining for this population is reported. All antibody data provided in this report were generated in a single screening assay using the same pool of target cells to allow for direct comparisons between samples collected in different experiments. Flow data analysis was performed using flow data-analysis software (FlowJo, LLC).
Whole blood staining for MHC
Whole blood was collected from C57Bl/6J and BALB/cJ mice into ethylene diamine tetraacetic acid tubes and diluted in phosphate-buffered saline (PBS). Blood was stained with anti-Ter119 (an RBC marker), anti-CD61 (a platelet marker), and anti-CD45 (a WBC marker), along with either anti-H2Db (a Class I MHC expressed by C57Bl/6J, but not BALB/cJ, mice), or anti-H2Dd (a Class I MHC expressed by BALB/cJ, but not C57Bl/6J, mice). Samples were run on a flow cytometer (LSRII; BD Biosciences), and sufficient events were collected to provide approximately 5000 WBCs for analysis. Cell populations were identified based on expression of the abovedescribed markers and forward and side scatter gating, and MHC expression was analyzed (FlowJo, LLC). To compare expression before and after treatment with UV1R, C57Bl/6J blood was collected into 14% CPD, and a portion was treated with UV1R as described above. A second portion was diluted equivalently with PBS in place of riboflavin and was left untreated for comparison. MFIs were compared against stains of BALB/cJ blood that were run at the same time to normalize values. Stains were done in Trucount tubes (BD Biosciences), and cell concentrations were calculated based on the number of beads per tube, the volume of blood added, and the ratio of beads to each cell type. Cells were stained but not fixed, and the samples were run between 2 and 3 hours after UV1R treatment (equivalent to the timing of transfusion post-treatment).
Cytokine detection
Freshly isolated splenocytes were cultured either alone or with mitomycin C-treated C57Bl/6J splenocytes (donortype stimulator cells). After 48 hours, culture supernatants were collected and frozen. Samples were later thawed and assayed using the Milliplex Map Mouse Cytokine/Chemokine Premixed 25 Plex kit (Millipore). Cytokines were measured with the Luminex 100 platform (Luminex) using BioManager Software (BioRad) for analysis as previously described. 24 
T reg detection
Frozen splenocytes were thawed and washed for staining. Cells were stained first with a LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (ThermoFisher Scientific) and then washed before surface staining. Surface stain included anti-CD4 Alexa Fluor 700 and anti-TCRb phycoerythrincyanine 5 (PE-Cy5). Cells were washed, fixed, and permeabilized; stained with anti-FoxP3 phycoerythrin-cyanine 7 (PE-Cy7), washed, and run on a flow cytometer (LSRII; BD Biosciences). The mean (6 standard deviation) splenocyte viability was 94.5 6 2.15%. Flow data-analysis software (FlowJo, LLC) was used to analyze the results.
Statistical analysis
Prism software (version 5.0f; GraphPad Software, Inc.) was used for analysis and to generate plots of all data. Groups were compared using one-way analysis of variance. Individual comparisons were made using either Dunnet's post-test (when comparing multiple groups with a single control sample), or Tukey's post-test (when comparing all groups with each other pairwise), as indicated in the figure legends.
RESULTS
BALB/cJ mice received either no transfusion or transfusions of allogeneic C57Bl/6J whole blood (Fig. 1) . Four different transfusion regimes were tested: 1) a single transfusion with nonleukoreduced blood; 2) a single transfusion with nonleukoreduced blood that had been pathogen reduced using UV1R; 3) a transfusion with UV1R-treated, nonleukoreduced blood followed 2 weeks later by a second transfusion with untreated, nonleukoreduced blood; or 4) the Group 3 transfusions given in reverse. Two weeks after their final transfusions, blood and spleens were collected.
Circulating antibodies were measured in each recipient by incubation of serum with splenocytes collected from C57Bl/6J (donor type) mice, followed by stains with anti-Igj antibody to detect bound antibodies and by antiTCRb and anti-B220 to detect T cells and B cells, respectively. MFI was measured in the TCRb-positive/B220-negative gate to measure levels of antibodies. This was done to exclude B cells (most of which express the Igj chain) and to focus on a uniform population. This limited our detection to antibodies against antigens expressed on T cells, predominantly Class I MHC, which is the dominant 'antigen in platelet alloimmunization, and it excluded the detection of antibodies against Class II MHC and platelet-specific antigens, although similar results were obtained using the TCRb-negative/B220-negative gate as targets, which should contain some Class II-expressing cells (data not shown). This also restricted our detection to antibodies using the Igj light chain, but these make up approximately 95% of the antibodies in mice. 57, 58 High levels of antibody were detected in the group that received a single untreated transfusion ( Fig. 2A) . In contrast, although they still had a detectible alloantibody response, those that received a single UV1R-treated transfusion had significantly lower levels of antibody than the mice that received untreated blood. Furthermore, when mice that received UV1R-treated transfusions subsequently received a transfusion of untreated blood from the same donor type, the antibody responses were lower than those in the mice that received only an untreated transfusion, suggesting the generation of weak humoral tolerance. This protection was order-specific, because the transfusion of UV1R-treated blood after a transfusion of untreated blood from the same donor type did not significantly alter antibody responses relative to mice that received a single untreated transfusion.
To evaluate the impact of PRT treatment with UV1R on leukoreduced whole blood, mice received either no whole-blood transfusion (UV1R B6, B6); or an untreated C57Bl/6J whole-blood transfusion followed 2 weeks later with a UV1R-treated C57Bl/6J whole-blood transfusion (B6, UV1R B6). Mice were killed 2 weeks after their final transfusion, and serum and splenocytes were harvested for further analysis.
transfusion or a single transfusion with either untreated leukoreduced C57Bl/6J whole blood or UV1R-treated, leukoreduced C57Bl/6J whole blood; and antibodies were measured in serum 2 weeks after transfusion. Levels of antibody were very low in recipients of leukoreduced whole blood, as expected, although they were still detectibly higher than those in nontransfused controls in the absence of UV1R treatment (Fig. 2B) . Levels of antibody in the mice that received UV1R-treated, leukoreduced whole blood fell between those in the nontransfused and untreated leukoreduced groups and were not significantly different from those in the untreated leukoreduced group.
To confirm that WBCs were the primary source of MHC alloantigen, whole blood from C57Bl/6J and BALB/cJ mice was stained with surface markers to identify WBC, platelet, and RBC subsets (Fig. 3A) , along with either antiH2Db (Fig. 3B) , or anti-H2Dd (Fig. 3C) . H2Db is the Class I MHC expressed by C57Bl/6J, but not BALB/cJ, mice; and H2Dd is a Class I MHC expressed by BALB/cJ, but not C57Bl/6J, mice. Matched cell populations from the strain that did not express each MHC were used as negative controls. As expected, high levels of Class I MHC were seen on WBCs, low levels were seen on platelets, and no expression was seen on RBCs. We next evaluated the effect of UV1R treatment on the size of each cell compartment and expression of Class I MHC within each cell type (Fig.  3D) . The concentration of each cell component was not affected by treatment (Fig. 3D, left) , but there was a slight reduction in Class I MHC associated with treatment in the WBC compartment (Fig. 3D, right ). There were slightly higher MFIs seen in the platelet and RBC compartments after treatment (Fig. 3D, right) , but these were most likely due to low-level expression in combination with weak fluorescence of the riboflavin, because the UV1R-treated unstained controls also were brighter in this channel than the untreated unstained controls (data not shown).
In addition to antibody responses, we evaluated ex vivo cytokine responses in splenocytes collected from the mice to look for signs of cell priming from in vivo alloantigen exposure. Freshly collected splenocytes were cultured either alone or with mitomycin C-treated splenocytes from C57Bl/6J (donor type) mice for 48 hours, and levels of cytokines were measured using a multiplexing technique (Fig. 4) . Cells from the nontransfused, na€ ıve mice produced several cytokines in response to stimulation with the allogeneic C57Bl/6J cells, but cytokine responses were significantly enhanced by prior exposure to C57Bl/6J antigens in the untreated transfused control group, demonstrating cell priming (Fig. 4A) . Mice that received UV1R-treated transfusions behaved more like the na€ ıve mice, with significantly reduced responses compared with those in the untreated transfusion controls. Furthermore, when mice that had received UV1R-treated transfusions subsequently received untreated transfusions, their responses for several cytokines were significantly lower than those produced by the untreated transfusion only. The one exception was interleukin 4 (IL-4), which was elevated in this group, and only this group, compared with the recipients of untreated transfusion only (Fig. 4B) . As observed in the antibody responses, this protection from priming was order-dependent, requiring exposure to the UV1R-treated product before the untreated product.
It has been demonstrated that T reg cells play a role in ECP-induced tolerance 31, 32 and in tolerance induced by UV-treated allogeneic WBCs in a different model system. 59 Because we observed signs of both humoral and cellular tolerance induction after transfusion with UV1R-treated allogeneic whole blood, we next assessed whether there was any evidence of elevated T reg cells in these mice. Cryopreserved splenocytes from these experiments were thawed and stained with our T reg flow cytometry panel. Live CD4-positive T cells were gated (Fig. 5A) , and the frequency of FoxP3-positive T reg cells was assessed in this population (Fig. 5B) . These frequencies were plotted by group, and no differences were observed between groups (Fig. 5C ).
DISCUSSION
In this study, we demonstrated that pathogen reduction treatment of whole blood with UV1R significantly reduces, but does not eliminate, the alloantibody response to foreign MHC. This treatment also blocks the priming of cytokine responses ex vivo, suggesting that other cellular responses may also be prevented. In addition, transfusion of UV1R-treated allogeneic whole blood induces some tolerance to subsequent exposures to the same alloantigens, with reduced alloantibody and cytokine responses after subsequent transfusion with untreated whole blood from the same donor. This tolerance does not appear to be mediated by T reg -cell induction, because the frequency of these cells is not elevated after UV1R-treated transfusion. These findings differ somewhat from what we have observed after the transfusion of UV1R-treated PRP. 24 Compared with treated PRP, UV1R treatment of whole blood provides less protection against the primary antibody response, with levels of antibody roughly one-half of those observed in untreated whole blood transfusion, but still significantly higher than those in the nontransfused controls. In contrast, protection against secondary exposure may be improved by whole blood treatment, because reduced antibody levels were observed after the transfusion of untreated whole blood in mice that received UV1R-treated blood from the same donor type first. This modulation of the humoral response has not been seen with UV1R-treated PRP transfusion. These differences in protection could be the result of the different cell composition of these products or the high dose of UV light used in the whole blood treatment.
Cytokine responses appear to be similar using the two different treated blood products, with high levels of protection observed after primary exposure and indications of tolerance after secondary exposure to the same donor type. IL-4 was the only cytokine that followed a different pattern in the current study, with slightly elevated levels seen in mice that received treated allogeneic whole blood transfusions before untreated transfusions. IL-4 is a 
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classic T-helper cell 2 cytokine, but no differences in the levels of other T-helper cell 2 cytokines, such as IL-5 or IL-13, were observed in this group (data not shown). Interestingly, it has been demonstrated that IL-4 is important in indirect allogeneic stimulation. The production of IL-4 by T cells during allogeneic stimulation in vitro stimulates the expression of B7.1 and B7.2 on antigen-presenting cells, and skin allograft rejection is reduced when IL-4 is blocked. 60 The higher levels observed in cells from mice that received treated allogeneic transfusion followed by untreated allogeneic transfusion may be the result of increased production or decreased use by tolerogenic antigen-presenting cells. Compared with what has been observed with ECP and some other UV-based treatments, 31, 32, 59 we did not see evidence of T reg expansion after the transfusion of UV1R-treated allogeneic whole blood. This failure to detect a difference in T reg levels could mean that non-T reg mechanisms are responsible for the tolerance we have observed or that the role they play does not result in a detectible increase in frequency at the time point evaluated here (2 weeks after the final transfusion). Leukoreduction alone resulted in a significant decrease in alloantibody responses that exceeded the protection seen with UV1R treatment alone. This is consistent with the expression of MHC alloantigen illustrated in Fig. 3 , because the majority of MHC alloantigen is derived from WBCs, and even the low MHC-expressing platelets are reduced with these leukoreduction filters. 61 When UV1R was combined with leukoreduction, the mean levels of detected antibody were approximately halfway between the nontransfused and leukoreduction only groups, but they were not significantly different from mean levels in the leukoreduction only group. This suggests that, if leukoreduction is already in place, then adding UV1R treatment may not provide meaningful additional protection against alloimmunization after a single whole blood transfusion. An additional benefit of combining these protective measures may be seen in recipients of repeated transfusions, as we have observed with repeated PRP transfusions.
25
UV1R treatment itself did not alter the levels of WBCs in the product, but it did result in a small reduction in their expression of Class I MHC, consistent with what we have seen with human WBCs in UV1R-treated plasma. 23 Although the numbers of WBCs, platelets, and RBCs in the transfused product were not altered by UV1R treatment, this treatment can decrease donor platelet survival in the recipient, as has been observed in both treated murine and human platelets, although it was more severe in a mouse model. 25, 62 Furthermore, it has been demonstrated that UV1R treatment of whole blood effectively kills WBCs in vitro. 33, 56 The clearance of dying WBCs or damaged platelets can result in indirect presentation of MHC antigens and may explain the partial tolerance observed with the transfusion of treated blood. The addition of a viable whole blood pathogen reduction treatment would help to close the gap in protection that is achievable with currently available treatments. Although UV1R pathogen reduction treatment does not appear to prevent RBC alloimmunization in mice, 55 it does appear to provide some protection against both primary and secondary WBC alloimmunization. This, in combination with protection from transfusiontransmission of infection and graft-versus-host disease, suggests that UV1R treatment may provide significant protection to transfusion recipients from these complications. As appropriate clinical data become available, additional work will be needed to determine whether this protection can be translated to human transfusion recipients.
